7.97
0.14 (1.79%)
| Penutupan Terdahulu | 7.83 |
| Buka | 7.83 |
| Jumlah Dagangan | 2,057,323 |
| Purata Dagangan (3B) | 2,715,815 |
| Modal Pasaran | 1,054,300,160 |
| Harga / Jualan (P/S) | 18.14 |
| Harga / Buku (P/B) | 9.18 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 4 Nov 2025 |
| Margin Operasi (TTM) | -788.76% |
| EPS Cair (TTM) | -1.20 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -16.70% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 22.16% |
| Nisbah Semasa (MRQ) | 6.26 |
| Aliran Tunai Operasi (OCF TTM) | -135.34 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -67.25 M |
| Pulangan Atas Aset (ROA TTM) | -26.79% |
| Pulangan Atas Ekuiti (ROE TTM) | -61.35% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Tango Therapeutics, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 4.0 |
| Purata | 0.63 |
|
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 12.59% |
| % Dimiliki oleh Institusi | 97.41% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 15.00 (Stifel, 88.21%) | Beli |
| Median | 14.00 (75.66%) | |
| Rendah | 12.00 (Guggenheim, 50.57%) | Beli |
| Purata | 13.67 (71.52%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 8.47 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Stifel | 04 Dec 2025 | 15.00 (88.21%) | Beli | 9.90 |
| B. Riley Securities | 18 Nov 2025 | 14.00 (75.66%) | Beli | 8.00 |
| Guggenheim | 24 Oct 2025 | 12.00 (50.56%) | Beli | 7.50 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 26 Nov 2025 | Pengumuman | Tango Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference |
| 12 Nov 2025 | Pengumuman | Tango Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference |
| 04 Nov 2025 | Pengumuman | Tango Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights |
| 29 Oct 2025 | Pengumuman | Tango Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 |
| 23 Oct 2025 | Pengumuman | Tango Therapeutics Announces $225 Million Financing |
| 23 Oct 2025 | Pengumuman | Tango Therapeutics Reports Positive Data from Ongoing Phase 1/2 Study with Vopimetostat (TNG462) in Patients with MTAP-deleted Cancers |
| 06 Oct 2025 | Pengumuman | Tango Therapeutics to Present First Clinical Data from TNG260 at Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |